about
Constitutive NF- κ B Activation Underlines Major Mechanism of Drug Resistance in Relapsed Refractory Diffuse Large B Cell LymphomaNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewEfficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.[Clinical Efficacy of Bleomycin, Cyclophosphamide, Vindesine, Ara-C and Dexamethasone for Treatment of Patients with Relapsed Refractory Diffuse Large B Cell Lymphoma].Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review.Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma.NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.Performance of 89Zr-Labeled-Rituximab-PET as an Imaging Biomarker to Assess CD20 Targeting: A Pilot Study in Patients with Relapsed/Refractory Diffuse Large B Cell LymphomaPhase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.Salvage therapy for relapsed/refractory diffuse large B cell lymphoma.Management of relapsed-refractory diffuse large B cell lymphoma.Relapsed/refractory diffuse large B-cell lymphoma.Relapsed/refractory diffuse large B-cell lymphoma: review of the management of transplant-eligible patients.Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed/ Refractory Diffuse Large B Cell Lymphoma.Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.R-ESHAP plus pegfilgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory diffuse large B-cell lymphoma.Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party.High-dose chemotherapy with autologous stem cell transplantation for elderly patients with relapsed/refractory diffuse large B cell lymphoma: a nationwide retrospective study.Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.Predictive value of [¹⁸F]fluoro-2-deoxy-D-glucose positron emission tomography for clinical outcome in patients with relapsed/refractory diffuse large B-cell lymphoma prior to and after autologous stem cell transplant.The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype.Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study.CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial.A bio-clinical prognostic model using MYC and BCL2 predicts outcome in relapsed/refractory diffuse large B-cell lymphoma.Blinatumomab in relapsed/refractory diffuse large B cell lymphoma.Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.[Advances in the Molecular Diagnosis and Therapy of Relapsed/Refractory Diffuse Large B-cell Lymphoma -Review].Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma.A phase II trial of AZD1152 in relapsed/refractory diffuse large B-cell lymphoma.Co-expression of MYC and BCL2 predicts poorer outcomes for relapsed/refractory diffuse large B-cell lymphoma with R-ICE and intent to transplant.Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana LinfomiMeta-analytical methods for estimating outcomes from overall response rate in patients with relapsed/refractory diffuse large B-cell lymphomaNivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II StudyRelapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapiesTreatment with cyclophosphamide, vindesine, cytarabine, dexamethasone and bleomycin in patients with relapsed/refractory diffuse large B-cell lymphomaCombination of albumin-bound paclitaxel and pegylated liposomal doxorubicin is effective in treatment of heavily treated relapsed/refractory diffuse large B-cell lymphoma: a case report
P921
Q26853170-6E8C6189-0329-4671-807D-A867BF5AC56AQ27304386-06B1753B-9DD7-4767-AB30-D4C272303CE6Q33413210-391194BA-B961-4A6A-BDE9-279F48D55D38Q33420631-B7376409-3640-4881-9BA2-5F182711945DQ33423933-8F27722C-7115-4B39-B789-B2F66202DAFBQ35157955-F7EA0A6B-2DAD-4397-8267-D99D0A2ACCEFQ35439403-D6F03ED3-5B81-4839-B97B-07CC9144FDD6Q35739680-A216D047-2BEE-47E8-AB99-5492985ECBB1Q36242716-2C4F5F13-EFA5-4806-9EF9-95C335443EBAQ36700470-AC19334A-5FB1-4D46-9497-933140F4C2C1Q37085060-4F887960-F9C1-4C18-A124-E9FEFC23E9AFQ37654010-E0768C6B-C2BD-46B3-969F-14E4215D8CCEQ37967335-95E747C6-8604-42F1-AB38-56A62B988089Q38210641-946E7D2F-0540-48C4-AA8B-3FD487B44FC5Q38891285-B03FF6C6-AA7B-4C32-BFD8-2B5365C5E9F8Q39028169-9D9F863A-D7A8-49DE-BAF8-C653E506B746Q39938060-62D1177A-670B-45D1-B9A2-1912855D3088Q40209671-B7955990-BCB6-437C-BBA3-62A3599FDE23Q41088166-465F27D8-D0E3-43E4-BC78-11A0C98BFF58Q42229931-D9ECC7A9-3BE9-4AA2-9B5F-4D0E91865522Q44841161-9EBFADFA-3C5C-47C2-ABDA-852C4488EAA4Q44841241-602A44E7-1E3E-40F0-BE2B-47901F9F507CQ44875676-B3806EF2-5FD7-4B50-983C-63D349178673Q45899999-1C3ECA6F-9F85-466E-81B3-23A3331D0A13Q46179089-510F3602-82DB-4505-AC6F-D7BFF1F586B8Q47109026-51CD5531-0B8B-4E5D-A4F4-6ADF92F24A64Q47447676-0701DFD0-2602-4ABA-8F83-0B99A4F26F2EQ48287421-E569831C-66AF-4FF1-85F9-E1A39066D966Q48503675-C66A61B2-DE20-4FA7-9DAF-381D37837A42Q51039125-4F5B2300-B547-4EAF-B790-89F8D4E736F3Q52718730-5F1D4D57-7B53-4227-BCC1-8C41BAA2E1FDQ53077918-FD7F955D-2A5C-4ACF-BD15-5580192B51FAQ54287946-A467E0E4-344A-4982-AB93-854AD9283B92Q55159641-A66CAF26-EACC-45FE-8AC5-F1844AF5B443Q56387600-62B6458A-DE22-4CD4-9720-5DA5E6CBD722Q64264563-0EAFB98D-2244-45FC-B0BD-B24A8D3B6152Q64272739-B3055F53-6087-4D1D-AE94-F6C3772D2BDDQ84280659-8F0F4612-777D-41C6-985A-95C4D8654196Q86044490-5F358F79-B7F7-4DA5-9838-B38580FD920EQ86187615-8C5E121F-C506-4E35-9689-6A037A1DB8D1
P921
description
diffuse large B-cell lymphoma ...... tainment of complete remission
@en
name
relapsed/refractory diffuse large B-cell lymphoma
@en
type
label
relapsed/refractory diffuse large B-cell lymphoma
@en
prefLabel
relapsed/refractory diffuse large B-cell lymphoma
@en
P31
P5270
MONDO:0000901
P699
DOID:0080192